Novian Health Raises $11 Million Series A; Ramps Up Studies Of Breast Cancer Laser Ablation
Executive Summary
Novian Health Inc. will use its recent $11 million Series A round to kickstart multicenter clinical trials on its Novilase Interstitial Laser Therapy for ablating early-stage breast cancer.
You may also be interested in...
Market Intel: New Thermal Therapies Blaze Trail In Fast-Growing Cancer Ablation Market
Cancer rates are rising worldwide and as diagnostic techniques continue to improve, new surgical ablation devices are becoming crucial weapons in the growing arsenal of cancer treatment tools. These devices allow doctors to burn away tumors with precision, speed and safety, without the side-effects that patients undergoing radical cancer therapy often experience. This article provides an overview of the cancer ablation market, highlights the key players working on these devices and discusses their potential applications. It also includes critical insights from a leading interventional urologist on the pros and cons of using these various technologies in treating prostate cancer.
The Evolving World Of Breast Cancer Management
The device industry is playing a pivotal role in the evolution toward a more personalized approach to breast cancer management, with ongoing advances in minimally invasive treatment systems, tumor characterization and breast imaging technologies adding to the momentum. In the years ahead, as the breast cancer toolbox expands, the watchword will be “choice,” with physicians and patients offered more treatment options, targeted to their specific needs and desires, than ever before.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.